Von Willebrand disease (VWD)

wilate® is indicated for:

Treatment and prevention of spontaneous and trauma-induced bleeds in all types of VWD in adult and pediatric patients where the use of DDAVP (1-deamino-8-D-arginine vasopressin/desmopressin) treatment is ineffective or contra-indicated. Clinical data on controlling severe spontaneous bleeding are limited, and only minimal data exist to support the prophylactic use of wilate®. Prevention and treatment of bleeding during and after surgical procedures. 

For more information please visit:

Adverse Events & Safety Considerations

  • Hypersensitivity or allergic reactions have been observed infrequently and may in some cases progress to severe anaphylaxis (including shock). On rare occasions, fever has been observed. Patients must be closely monitored and carefully observed for any symptoms throughout the infusion period.

  • This product is prepared from large pools of human plasma, which may contain the causative agents of hepatitis and other viral diseases. The physician should discuss the risks and benefits of this product with the patient before prescribing or administering it to the patient.


  • wilate® is contraindicated for patients who are hypersensitive to this drug or to any ingredient in the formulation or component of the container.